FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Salmon Strengthens Fundraising for Philippines Expansion

Fintech company Salmon secures new funding to enhance its operations in the Philippines.Highlights: Salmon raises significant funds to...
FinTech

Truist Pilots Zelle Bill Payments, Strengthening Digital Banking Services

New pilot program aims to simplify bill payments through Zelle for customers.Highlights: Truist launches pilot program for Zelle...
FinTech

ACI Worldwide Strengthens Payment Solutions with Cloud-Native Platform

New platform enhances support for eight U.S. payment networks.Highlights: ACI Worldwide launches a cloud-native payment platform.The platform supports...
FinTech

LendingClub Rebrands as Happen Bank, Strengthens Digital Banking Services

The transformation aims to enhance customer engagement and streamline services.Highlights: LendingClub officially rebrands to Happen Bank.The rebrand focuses...